ECO Animal Health Group (LON:EAH) Stock Passes Above 50 Day Moving Average – Here’s Why

ECO Animal Health Group plc (LON:EAH) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 106.77 and traded as high as GBX 108.17. ECO Animal Health Group shares last traded at GBX 103, with a volume of 94,318 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group lifted their price target on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of GBX 160.

ECO Animal Health Group Stock Down 2.8%

The company has a quick ratio of 2.14, a current ratio of 2.96 and a debt-to-equity ratio of 4.81. The business has a 50-day simple moving average of GBX 106.77 and a two-hundred day simple moving average of GBX 93.09. The stock has a market capitalization of £69.10 million, a P/E ratio of 23.46 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last posted its earnings results on Monday, December 1st. The company reported GBX (0.54) earnings per share for the quarter. ECO Animal Health Group had a return on equity of 1.27% and a net margin of 1.17%.

Insider Activity

In other news, insider David Hallas bought 18,348 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was bought at an average price of GBX 109 per share, for a total transaction of £19,999.32. Company insiders own 11.17% of the company’s stock.

ECO Animal Health Group Company Profile

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.